##### Table of Contents



SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
 FORM 10-Q (Mark One) [X]
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934
 For the quarterly period ended March 31, 2004 OR [ ]
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934
 For the transition period from            to Commission file number 000-31019


ARGONAUT TECHNOLOGIES, INC.



DELAWARE
(State or other jurisdiction of
incorporation or organization)
    
    94-3216714
(IRS Employer
Identification Number)


1101 Chess Drive
Foster City, CA 94404
(Address of principal executive offices, including zip code)

(650) 655-4200
(Registrants telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes [ ] No
[X]

There were 20,491,002 shares of the registrants common stock outstanding on
April 30, 2004.





---



Argonaut Technologies, Inc.
Form 10-Q
Quarterly Period Ended March 31, 2004 TABLE OF CONTENTS PART I:
    
    FINANCIAL INFORMATIONItem 1.
    
    Financial Statements
    
    
    3Condensed Consolidated Balance Sheets as of March 31, 2004 (Unaudited) and December 31, 2003
    
    
    3Condensed Consolidated Statements of Operations for the Three-Month Periods Ended March 31, 2004 and 2003(Unaudited)
    
    
    4Condensed Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2004 and 2003(Unaudited)
    
    
    5Notes to Condensed Consolidated Financial Statements (Unaudited)
    
    
    6Item 2.
    
    Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    9Item 3.
    
    Quantitative and Qualitative Disclosures About Market Risk
    
    
    17Item 4.
    
    Controls and Procedures
    
    
    17PART II:
    
    OTHER INFORMATIONItem 1.
    
    Legal Proceedings
    
    
    18Item 2.
    
    Changes in Securities and Use of Proceeds
    
    
    18Item 3.
    
    Defaults Upon Senior Securities
    
    
    18Item 4.
    
    Submission of Matters to a Vote of Security Holders
    
    
    18Item 5.
    
    Other Information
    
    
    18Item 6.
    
    Exhibits and Reports on Form 8-K
    
    
    19SIGNATURES
    
    
    21EXHIBIT INDEX
    
    
    22EXHIBIT 10.19EXHIBIT 10.20EXHIBIT 31.1EXHIBIT 31.2EXHIBIT 32.1EXHIBIT 32.2
  Page 2 of 23




---



##### Table of Contents



PART I: FINANCIAL INFORMATION 
 ITEM 1. FINANCIAL STATEMENTS 
 ARGONAUT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands) March 31,
    
    December 31,2004
    
    2003(Unaudited)
    
    (Note 1)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    10,688
    
    
    $
    9,620Short-term investments
    
    
    99
    
    
    
    3,850Accounts receivable, net
    
    
    4,359
    
    
    
    5,993Inventories
    
    
    7,433
    
    
    
    6,946Prepaid expenses & other current assets
    
    
    659
    
    
    
    562Notes receivable
    
    
    64
    
    
    
    56Total current assets
    
    
    23,302
    
    
    
    27,027Restricted cash
    
    
    12,883
    
    
    
    12,317Property and equipment, net
    
    
    4,085
    
    
    
    4,454Goodwill
    
    
    9,410
    
    
    
    9,410Other intangible assets, net
    
    
    4,316
    
    
    
    4,471Long-term investments
    
    
    6,272
    
    
    
    5,432Other assets
    
    
    201
    
    
    
    204$
    60,469
    
    
    $
    63,315LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    1,280
    
    
    $
    1,494Accrued compensation
    
    
    800
    
    
    
    971Other accrued liabilities
    
    
    2,099
    
    
    
    2,406Deferred revenue
    
    
    736
    
    
    
    978Current portion of notes payable and capital lease obligations
    
    
    12,613
    
    
    
    12,200Total current liabilities
    
    
    17,528
    
    
    
    18,049Long term debt
    
    
    21
    
    
    
    23Stockholders equity:Common stock
    
    
    2
    
    
    
    2Additional paid-in capital
    
    
    121,632
    
    
    
    121,670Deferred stock compensation
    
    
    (6
    )
    
    
    (9
    )Accumulated other comprehensive income (loss)
    
    
    1,062
    
    
    
    824Accumulated deficit
    
    
    (79,770
    )
    
    
    (77,244
    )Total stockholders equity
    
    
    42,920
    
    
    
    45,243$
    60,469
    
    
    $
    63,315
 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Page 3 of 23




---



##### Table of Contents



ARGONAUT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited) Three Months EndedMarch 31,2004
    
    2003Net sales:Products
    
    $
    4,241
    
    
    $
    5,244Services
    
    
    439
    
    
    
    1,009Total net sales
    
    
    4,680
    
    
    
    6,253Costs and Expenses:Costs of products
    
    
    3,089
    
    
    
    2,836Costs of services
    
    
    224
    
    
    
    661Research and development (Note A)
    
    
    945
    
    
    
    1,293Selling, general and administrative (Note A)
    
    
    3,046
    
    
    
    3,790Amortization of purchased intangibles
    
    
    121
    
    
    
    211Total costs and expenses
    
    
    7,425
    
    
    
    8,791Loss from operations
    
    
    (2,745
    )
    
    
    (2,538
    )Other income (expenses):Interest and other income
    
    
    329
    
    
    
    243Interest and other expense
    
    
    (137
    )
    
    
    (178
    )Net loss before provision for income taxes
    
    
    (2,553
    )
    
    
    (2,473
    )Income taxes benefit (provision)
    
    
    27
    
    
    
    (58
    )Net loss
    
    $
    (2,526
    )
    
    $
    (2,531
    )Net loss per common share, basic and diluted
    
    $
    (0.12
    )
    
    $
    (0.13
    )Weighted-average shares used in
computing net loss per common share, basic and diluted
    
    
    20,397
    
    
    
    20,022Note A: Research and development expenses and selling, general and administrative
expenses include charges for stock-based compensation as follows:Research and development
    
    $
    
    
    
    $
    13Selling, general and administrative
    
    
    
    
    
    
    18$
    
    
    
    $
    31
 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Page 4 of 23




---



##### Table of Contents



ARGONAUT TECHNOLOGIES, INC. 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 Three Months EndedMarch 31,2004
    
    2003Cash flows from operating activities:Net loss
    
    $
    (2,526
    )
    
    $
    (2,531
    )Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization
    
    
    293
    
    
    
    346Amortization of other purchased intangibles
    
    
    155
    
    
    
    226Disposal of fixed assets
    
    
    106
    
    
    
    35Stock-based compensation
    
    
    
    
    
    
    31Change in cumulative translation adjustment
    
    
    (11
    )
    
    
    63Changes in assets and liabilities:Accounts receivable
    
    
    1,645
    
    
    
    212Inventories
    
    
    (487
    )
    
    
    (265
    )Prepaid expenses and other current assets
    
    
    (71
    )
    
    
    (30
    )Accounts payable
    
    
    (214
    )
    
    
    (34
    )Accrued compensation
    
    
    (171
    )
    
    
    (22
    )Other accrued liabilities
    
    
    (308
    )
    
    
    (505
    )Deferred revenue
    
    
    (242
    )
    
    
    (415
    )Net cash used in operating activities
    
    
    (1,831
    )
    
    
    (2,889
    )Cash flows from investing activities:Capital expenditures
    
    
    (61
    )
    
    
    (378
    )Purchase of short-term investments
    
    
    
    
    
    
    (3,179
    )Proceeds from the sales of short-term investments
    
    
    771
    
    
    
    4,622Proceeds from the maturities of short-term investments
    
    
    3,007
    
    
    
    Purchase of long-term investments
    
    
    (840
    )
    
    
    Purchase of licenses
    
    
    
    
    
    
    (35
    )Restricted cash
    
    
    (154
    )
    
    
    Net cash provided by investing activities
    
    
    2,723
    
    
    
    1,030Cash flows from financing activities:Principal payments on capital lease obligations
    
    
    
    
    
    
    (30
    )Repayment of long term debt
    
    
    
    
    
    
    (71
    )Repurchase of common stock
    
    
    (81
    )
    
    
    Net proceeds from issuances of common stock
    
    
    47
    
    
    
    6Net cash used in financing activities
    
    
    (34
    )
    
    
    (95
    )Effect of exchange rate changes on cash
    
    
    210
    
    
    
    Net increase (decrease) in cash and cash equivalents
    
    
    1,068
    
    
    
    (1,954
    )Cash and cash equivalents at beginning of period
    
    
    9,620
    
    
    
    20,895Cash and cash equivalents at end of period
    
    $
    10,688
    
    
    $
    18,941
 The accompanying notes are an integral part of these unaudited condensed consolidated financial
statements. Page 5 of 23




---



##### Table of Contents



ARGONAUT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1  BASIS OF PRESENTATION AND NEW ACCOUNTING STANDARDS Basis of presentation The accompanying unaudited condensed consolidated financial statements have
been prepared in conformity with generally accepted accounting principles in
the United States for interim financial information and with the instructions
to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not contain
all of the information and footnotes required by generally accepted accounting
principles in the United States for complete financial statements. In the
opinion of management, the accompanying unaudited condensed consolidated
financial statements contain all adjustments, consisting of normal recurring
accruals and adjustments, which Argonaut Technologies, Inc. (Argonaut or the
Company) considers necessary to present fairly the financial information
included herein. The condensed consolidated balance sheet at December 31, 2003
has been derived from the audited consolidated financial statements at that
date but does not include all of the information and footnotes required by
accounting principles generally accepted in the United States for complete
financial statements. This Quarterly Report on Form 10-Q should be read in
conjunction with the audited consolidated financial statements and notes
thereto included in the Companys Form 10-K, for the year ended December 31,
2003 as filed with the Securities and Exchange Commission. The interim results
presented herein are not necessarily indicative of the results of operations
that may be expected for the full fiscal year ending December 31, 2004, or any
other future period. Product Warranty The Company generally warrants its equipment for a period of one year and
provides a reserve for estimated warranty costs concurrent with the recognition
of revenue. The Company also sells warranty extensions and the related revenue
is recognized ratably over the term of the extension. Warranty costs incurred
during the extension period are expensed as incurred. Changes in the Companys product warranty accrual for the three months ended
March 31, 2004 and 2003 are as follows (in thousands): IncreaseBalance
    
    (Decrease) in
    
    Cost of
    
    BalanceAccrued Product Warranty
    
    Beginning
    
    Warranty
    
    Warranty
    
    End ofThree Months Ended:
    
    of Period
    
    Accrual
    
    Repair
    
    PeriodMarch 31, 2004
    
    $
    199
    
    
    
    51
    
    
    
    (17
    )
    
    $
    233March 31, 2003
    
    $
    211
    
    
    
    (22
    )
    
    
    (100
    )
    
    $
    89
 New Accounting Standards In January of 2003, the FASB issued FIN No. 46, Consolidation of Variable
Interest Entities. FIN No. 46 requires a variable interest entity (VIE) to
be consolidated by a company if that company is considered to be the primary
beneficiary in a VIE. Primary beneficiary is the party subject to a majority
of the risk of loss from the variable interest entitys activities or entitled
to receive a majority of the entitys residual returns or both. The
requirements of FIN No. 46 apply immediately to
VIEs created after January 31, 2003. The consolidation requirements apply to
older entities in the first fiscal year or interim period ending after March
15, 2004. The Company does not believe that it currently has any investments
in variable interest entities, therefore the adoption of FIN 46 did not have a
material impact on the Companys financial condition or results of operations. NOTE 2  STOCK-BASED COMPENSATION The Company accounts for its stock-based employee compensation as permitted by
Statement of Financial Accounting Standard No. 123, Accounting for Stock-Based
Compensation  (SFAS 123), as amended by Statement of Financial Page 6 of 23




---



##### Table of Contents



Accounting
Standard No. 148, Accounting for Stock-Based Compensation  Transition and
Disclosure, whereby stock-based employee compensation arrangements are
accounted for under the intrinsic value method prescribed by Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees
(APB 25). Under APB 25, when the exercise price of the Companys stock
options is less than the market price of the underlying shares on the date of
grant, compensation expense is recognized. Pro forma information regarding net
loss per share is required by SFAS 123 as if the Company had accounted for its
employee stock options under the fair value method of SFAS 123. The fair value
of these options granted prior to the Companys initial public offering in July
2000 was estimated at the date of grant using the minimum value method. The
fair value of stock options granted subsequent to the initial public offering
were valued using the Black-Scholes valuation model based on the actual stock
closing price on the date of grant. The fair value of these options was
estimated at the date of grant using the following weighted-average
assumptions: Three Months Ended March 31,2004
    
    2003Risk-free interest rate
    
    
    1.58
    %
    
    NADividend yield
    
    
    
    
    
    NAWeighted-average expected life
    
    
    3.6
    
    
    NAVolatility
    
    
    0.81
    
    
    NA
 The pro forma disclosures required by SFAS 123 are as follows (in thousands,
except per share amounts): Three Months Ended March 31,2004
    
    2003Net loss, as reported
    
    $
    (2,526
    )
    
    $
    (2,531
    )Stock-based employee compensation expense included in
reported net loss
    
    
    3
    
    
    
    26Total stock-based employee compensation expense
determined under fair value based methods for all awards
    
    
    (350
    )
    
    
    (372
    )Pro forma net loss
    
    $
    (2,873
    )
    
    $
    (2,877
    )Basic and diluted net loss per common share, as reported
    
    $
    (0.12
    )
    
    $
    (0.13
    )Pro forma basic and diluted net loss per common share
    
    $
    (0.14
    )
    
    $
    (0.14
    )
 Equity instruments granted to non-employees are accounted for using the
Black-Scholes valuation model prescribed by SFAS 123 and, in accordance with
Emerging Issues Task Force Consensus No. 96-18, Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring or in
Conjunction with Selling Goods or Services. The equity instruments are
subject to periodic revaluations over their vesting terms. The expense is
recognized as the instruments vest. NOTE 3  INVENTORIES Inventories consist of the following (in thousands): March 31,
    
    December 31,2004
    
    2003Raw materials
    
    $
    5,356
    
    
    $
    5,063Work in process
    
    
    583
    
    
    
    429Finished goods
    
    
    1,494
    
    
    
    1,454$
    7,433
    
    
    $
    6,946
 Page 7 of 23




---



##### Table of Contents



NOTE 4  NET LOSS PER SHARE Net loss per share has been computed according to Statement of Financial
Accounting Standards (SFAS) No. 128, Earnings Per Share, which requires
disclosure of basic and diluted earnings per share. Basic and diluted net loss
per share was computed using the weighted-average number of common shares
outstanding during the period. Due to the net loss position of the Company,
diluted earnings per share is calculated using the weighted average number of
common shares outstanding and excludes the effects of potential common shares
that are antidilutive. Options to purchase 3,749,995 and 3,932,216 shares of
common stock were outstanding at March 31, 2004 and March 31, 2003,
respectively. Warrants to purchase 63,065 and 80,665 shares of common stock
were outstanding at March 31, 2004 and March 31, 2003, respectively. Options
and warrants were not included in the computation of diluted net loss per
share, since the effect would be antidilutive. NOTE 5  COMPREHENSIVE LOSS Comprehensive loss is comprised of net loss and other items of comprehensive
income (loss). Other comprehensive income (loss) includes unrealized gains and
losses on the Companys short-term investments and foreign currency translation
adjustments. For the three-month periods ended March 31, 2004 and 2003, comprehensive loss
is as follows (in thousands): Three Months EndedMarch 31,2004
    
    2003Net loss
    
    $
    (2,526
    )
    
    $
    (2,531
    )Unrealized gain (loss)
    
    
    28
    
    
    
    (6
    )Cumulative translation adjustment
    
    
    210
    
    
    
    56Comprehensive loss
    
    $
    (2,288
    )
    
    $
    (2,481
    )
 NOTE 6  GOODWILL AND OTHER PURCHASED INTANGIBLES Goodwill and other purchased intangible assets with indefinite lives have
resulted from the acquisition of Camile Products, LLC (now Argonaut
Technologies Systems, Inc. (ATSI)) and Jones Chromatography Limited (the
Jones Group). Goodwill and other intangible assets with indefinite lives are
not amortized subsequent to the Companys adoption of SFAS 142, Goodwill and
Other Intangible Assets (SFAS 142). All goodwill and intangible assets have been assigned to one of two reporting
units. The Argonaut (AGNT)-Legacy reporting unit consists primarily of
goodwill and intangible assets related to the Companys acquisition of ATSI.
The Jones-Group reporting unit consists of goodwill and intangible assets
deriving from the Companys acquisition of Jones Chromatography, Ltd. During the third quarter ended September 30, 2003 the Company performed an
interim test for goodwill impairment in light of lower than expected third
quarter revenue. Based on the discounted cash flows of the AGNT-Legacy
reporting unit, the Company recognized an impairment charge of $1.6 million
relating to the goodwill and intangible assets associated with ATSI.
Approximately $763,000 of the impairment charge was related to goodwill
associated with ATSI, and the remainder was related to completed technology
assets associated with the acquisition of ATSI. The Company performed the annual test for impairment of intangible assets with
indefinite lives as prescribed by SFAS 142 during the fourth quarter of fiscal
2003, determining that no further impairment was indicated. The Company
determined the fair value of intangible assets with indefinite lives based on a
present value analysis of the discounted future cash flows. Page 8 of 23




---



##### Table of Contents



The amortization expense relating to the intangible assets for the three-month
periods ended March 31, 2004 and 2003 was 155,000 and $226,000, respectively.
The following represents the gross carrying amounts and accumulated
amortization of amortized intangible assets at March 31, 2004: GrossCarrying
    
    AccumulatedAmount
    
    AmortizationAmortized intangible assets:Completed technology
    
    $
    5,539
    
    
    $
    (2,637
    )Licenses
    
    
    1,435
    
    
    
    (214
    )Tradenames
    
    
    250
    
    
    
    (57
    )Total
    
    $
    7,224
    
    
    $
    (2,908
    )
 NOTE 7  RESTRUCTURING CHARGES On August 8, 2002, the Company announced its intention to execute a
restructuring program focused on improving productivity, reducing operational
expenses in remote offices, and implementing a workforce reduction of
approximately 20% of its existing worldwide employees. As a result, the
Company recognized a charge of $1.8 million in the third quarter ended
September 30, 2002. The charge included termination benefits and related
expenses of approximately $630,000 related to the reduction of the workforce by
44 employees, expenses of approximately $683,000 related to the abandonment of
excess equipment, expenses of approximately $356,000 for the abandonment of
excess leased facilities, and expenses of approximately $133,000 for various
other related charges. At March 31, 2004, 40 of the 44 employees had been
terminated. A summary of the restructuring activity is as follows (in thousands): Accrued
    
    
    
    
    
    Noncash
    
    AccruedRestructuring at
    
    Cash
    
    Charges
    
    Restructuring atDecember 31, 2003
    
    Payments
    
    (Recoveries)
    
    March 31, 2004Workforce reductions
    
    $
    70
    
    
    $
    
    
    
    $
    
    
    
    $
    70Abandonment of excess leased facilities
    
    
    88
    
    
    
    (33
    )
    
    
    
    
    
    
    55Total
    
    $
    158
    
    
    $
    (33
    )
    
    $
    
    
    
    $
    125
 
 ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS This quarterly report contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995, and it is the Companys
intention that such statements be protected by the safe harbor created thereby.
Examples of such forward-looking statements include statements regarding
future revenues, expenses, losses and cash flows, research and development
activities and sales and marketing initiatives such as our plan to concentrate
our efforts in those areas such as building our core consumables business,
possible future acquisitions, our plans to discontinue non-performing
consumable products and certain legacy instrument products, the anticipated
effects of our recent restructuring program and related accruals, values of our
assets and liabilities over their remaining useful lives and our testing for
impairment of goodwill, and our expectations as to the duration of our negative
cash flows from operations and the sufficiency of existing cash reserves for
the next 12 months. Actual results may differ materially from those projected
in such forward-looking statements due to various known and unknown risks and
uncertainties, including the risk that a decline in the economy generally or
the market for our products will adversely affect our business, the risk that
the market for our products and services does not develop as anticipated, the
risk that we are unable to successfully integrate the product and service
offerings of the companies we recently acquired and successfully capitalize on
anticipated synergies and growth opportunities, and the risk that our
restructuring programs do not proceed as planned and that we incur unexpected
expenses in connection with the implementation thereof. For a further
discussion of these and other risks and uncertainties related to our business
see the discussion set forth herein under Factors That May Affect Our Future
Results. Page 9 of 23




---



##### Table of Contents



Overview Argonaut develops innovative products designed to help pharmaceutical and other
chemists engaged in the discovery and development of new chemical entities
increase their productivity and reduce their operating costs without
compromising the scientific integrity of their research. Our products are
designed to enable chemists to increase their productivity, reduce their
operating costs through automation and process simplification, and cost
effectively explore the increasing number of drug targets available for drug
development. We derive revenues primarily from the sale of our chemistry
consumable products, instrumentation products and services. We commenced
commercial shipment of our first generation instrument in 1996, the Quest
product line in 1997, the Trident product line in 1998 and the Surveyor and the
Endeavor product lines in 2000. We also derive revenues from the sale of
reagents, and other instrument-related consumables and consumables products of
Jones Chromatography Limited (Jones Group), which we acquired on February 20,
2002. Our expenses have consisted primarily of costs incurred in research and
development, manufacturing and general and administrative costs associated with
our operations, and our sales and marketing organization. Since our inception,
we have incurred significant losses and, as of March 31, 2004, we had an
accumulated deficit of $79.8 million. Recent Developments New product introduction In the first quarter of 2004, we launched the FlashMaster Personal+ system and
the Advantage Series 2410 personal screening synthesizer, and both of these
products are important to our ability to increase revenues in 2004 and beyond.
Designed for use with pre-packed, disposable ISOLUTE® flash chromatography
columns, the FlashMaster Personal+ system features a second column position for
on-line solid sample loading and a liquid injection port for soluble samples.
The 2410 personal screening synthesizer is designed to help process chemists
who work with small amounts of material, simulate and replicate the thermal and
mixing conditions seen in larger production reactors. Critical Accounting Policies There have been no material changes to the Companys critical accounting
policies that are included/described in our Form 10-K for the year ended
December 31, 2003 filed with the Securities and Exchange Commission on March
30, 2004. RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2004 Net Sales Net sales in the three-month period ended March 31, 2004 were $4.7 million
compared to $6.3 million for the same period in 2003, a decrease of 25%. The
decrease in net sales is primarily due to the discontinuation of certain
non-strategic product
lines during 2003, the winding down of a contract research and development
(R&D) project, and decreased integration services sales. For the first
quarter of 2004, instrument sales comprised approximately 30% of net sales,
chemistry consumables sales comprised approximately 58% of net sales, and
service, integration services and contract R&D together comprised approximately
12% of net sales. Instrument sales were $1.4 million in the first quarter of
2004 versus $1.8 million for the same period in 2003, primarily due to the
discontinuation of certain product lines during 2003. Chemistry consumables
sales were $2.7 million in the first quarter of 2004 versus $3.3 million in the
same period of 2003, a decrease of 17%. The decline in chemistry consumables
products is primarily attributable to the sale of certain product lines to a
third party in 2003. Service, integration services and contract R&D sales were
$551,000 in the first quarter of 2004 versus $1.3 million in the same period of
2003, a decrease of about 55%. The decline is primarily due the winding down
of a contract R&D project and decreased integration services sales. Cost of sales Gross margin as a percent of sales was 29.2% for the first quarter of 2004
compared to 44.1% for the first quarter of 2003. Lower margin performance was
primarily due to the fact that lower revenue did not support the relatively
fixed manufacturing costs. In addition, we incurred costs of approximately
$211,000 due to the transfer of the manufacturing of our flash chromatography
instrument business from Cardiff, Wales to Foster City, California and the
transfer of a chemistry resins business from Foster City to Cardiff. There was
also an additional inventory write-off due to a discontinued product line. Page 10 of 23




---



##### Table of Contents



Research and development expenses Research and development expenses decreased to $0.9 million for the three-month
period ended March 31, 2004 compared to $1.3 million for the same period in
2003, a decrease of 27%. These expenses include salaries and related costs of
research and development personnel, fees paid to consultants and outside
service providers, the costs of facilities and related expenses, non-recurring
engineering charges and prototype costs related to the design, development
testing, pre-manufacturing and significant improvement of our products. The
decrease was primarily attributable to lower personnel costs and lower outside
service providers resulting from the effects of the restructuring program
initiated in the third quarter of 2002 and fewer ongoing R&D projects. Selling, general and administrative expenses Selling, general and administrative expenses decreased to $3.0 million in the
three-month period ended March 31, 2004 from $3.8 million for the same period
in 2003, a decrease of 20%. These expenses consist primarily of salaries and
related costs for executive, sales and marketing, finance and other
administrative personnel, the cost of facilities and related spending, and the
costs associated with promotional and other marketing expenses. The decrease
was primarily attributable to the effects of the restructuring efforts
initiated in the third quarter of 2002, lower personnel costs, and lower costs
associated with promotional expenses. Restructuring charges On August 8, 2002, the Company announced its intention to execute a
restructuring program focused on improving productivity, reducing operational
expenses in remote offices, and implementing a workforce reduction of
approximately 20% of the existing worldwide employees. As a result, the
Company recognized a charge of $1.8 million in the third quarter ended
September 30, 2002. The charge included termination benefits and related
expenses of approximately $630,000 related to the reduction of our workforce by
44 employees, expenses of approximately $683,000 related to the abandonment of
excess equipment, expenses of approximately $356,000 for the abandonment of
excess leased facilities, and expenses of approximately $133,000 for various
related charges. The restructuring program is estimated to result in
annualized savings of approximately $3.0 million beginning in fiscal 2003,
realized primarily in reduced operating costs as a result of reduced
employee-related costs. As of March 31, 2004, 40 of the 44 employees had been
terminated. The remaining accrued restructuring liability was $158,000 at
March 31, 2004. For the quarterly period ended March 31, 2004, there were
$33,000 of cash payments related to the restructuring program. Remaining cash
expenditures relating to workforce reduction and other related charges are
expected to be paid by June 30, 2004. Amounts related to the abandonment of
excess leased facilities will be paid as the lease payments are due over the
remainder of the lease terms through 2004. Amortization of purchased intangible assets For the quarter ended March 31, 2004, as part of operating expenses, the
Company recorded amortization of purchased intangibles of $121,000 compared to
$211,000 in the same period in 2003. The decrease in amortization expense is
due to the lower carrying value of the purchased intangible assets. Interest and Other Income (Expense), net Interest and other income increased to $329,000 for the three-month period
ended March 31, 2004 as compared to $243,000
for the same period in 2003, primarily because of the effects of foreign
currency transaction differences. Interest and other expense was $137,000 for
the first quarter of 2004 compared to $178,000 in the same period in 2003
primarily due to lower interest expense associated with a lower outstanding
balance of the notes payable for the Jones Group acquisition. Provision for Income Taxes The Company recorded a benefit for income taxes of approximately $27,000 due to
the loss before taxes of Jones Group in the UK for the three-month period ended
March 31, 2004 as compared to provision for income taxes of approximately
$53,000 to record the UK corporate tax liability of Jones Group for the same
period in 2003. LIQUIDITY AND CAPITAL RESOURCES As of March 31, 2004, the Company had cash, cash equivalents, investments and
restricted cash of $29.7 million compared to $31.2 million at December 31,
2003. The decrease was primarily due to the use of $1.8 million in general
operating activities, $0.8 million for purchase of long-term investments,
$81,000 for the repurchase of its common stock and $61,000 used for capital
expenditures. These uses of cash were offset by approximately $3.7 million in
proceeds from sales and maturities of short-term investments. Page 11 of 23




---



##### Table of Contents



At March 31, 2004, restricted cash of $12.9 million is comprised of $12.6
million that is used to secure the notes payable as purchase consideration in
the acquisition of the Jones Group and $0.3 million as deposits against
operating leases. At March 31, 2004, approximately $1.3 million of the note
principal had been paid, with the remainder ($12.6 million at March 31, 2004)
payable at April 30, 2004. Net cash used to support operating activities has historically fluctuated based
on the timing of payments of accounts payable balances, receipts of customer
deposits, receipt of payments of accounts receivable balances, changes in
inventory balances resulting from varying levels of manufacturing activities,
the timing of research and development projects, the timing and scope of our
sales and marketing initiatives and fluctuations in the Companys net loss. On August 8, 2002, the Company announced the approval by its Board of Directors
of a stock repurchase program pursuant to which shares of its outstanding
common stock having an aggregate value of up to $500,000 may be repurchased
through open market transactions at prices deemed appropriate by the Company.
The duration of the stock repurchase program is open-ended. The timing and
amount of repurchase transactions under this program will depend on market
conditions, corporate and regulatory considerations, and will be funded from
available working capital. During the three months ended March 31, 2004, the
Company repurchased 50,000 shares of its common stock on the open market for
approximately $81,000 at an average price of $1.62 per share. Through March 31,
2004, the Company had repurchased 100,000 shares of its outstanding common
stock at an average price of $1.28, pursuant to our stock repurchase program. The Company expects to have negative cash flows from operations through at
least the fourth quarter of 2004. We may also use cash resources to fund
additional collaborative or strategic relationships, acquisitions or
investments in other businesses, technologies or product lines. Based on our
current expectations, we believe that our current cash balances will be
sufficient to fund our operations through at least the next 12 months. At March 31, 2004, there have not been any substantial changes to the Companys
contractual cash obligations from those reported at December 31, 2003. New Accounting Standards In January of 2003, the FASB issued FIN No. 46, Consolidation of Variable
Interest Entities. FIN No. 46 requires a variable interest entity (VIE) to
be consolidated by a company if that company is considered to be the primary
beneficiary in a VIE. Primary beneficiary is the party subject to a majority
of the risk of loss from the variable interest entitys activities or entitled
to receive a majority of the entitys residual returns or both. The
requirements of FIN No. 46 apply immediately to VIEs created after January 31,
2003. The consolidation requirements apply to older entities in the first
fiscal year or interim period ending after March 15, 2004. The Company does
not believe that it currently has any investments in variable interest
entities, therefore the adoption of FIN 46 did not have a material impact on
the Companys financial condition or results of operations. FACTORS THAT MAY AFFECT OUR FUTURE RESULTS We have a history of operating losses and we may never achieve or sustain
profitability and may be required to raise additional funds if losses continue. We have incurred operating losses and negative cash flows from operations since
our inception. As of March 31, 2004, we had an accumulated deficit of $79.8
million and we recorded net losses of $2.5 million for the three-month period
ended March 31, 2004. We expect to continue to incur operating and net losses
during 2004 and we may never generate positive cash flows. Our future capital requirements depend on a number of factors, including market
acceptance of our products, the resources we devote to developing and
supporting our products, continued progress of our research and development of
potential products, the need to acquire licenses to new technology and the
availability of other financing on acceptable terms. To the extent that our
capital resources are insufficient to meet future capital requirements, we will
need to raise additional capital or incur indebtedness to fund our operations.
To the extent that we raise additional capital through the sale of equity, the
issuance of those securities will result in dilution to our stockholders. There
can be no assurance that additional debt or equity financing will be available
on acceptable terms, if at all. If adequate funds are not available, we may be
required to delay, reduce the scope of, or eliminate, our operations. We may
be required to obtain funds through arrangements with Page 12 of 23




---



##### Table of Contents



collaborative or
strategic partners or others that may require us to relinquish rights to
certain technologies or products that we might otherwise seek to retain. If our products do not become widely used in the pharmaceutical, biotechnology,
life sciences and chemical industries, it is unlikely that we will ever become
profitable. Pharmaceutical, biotechnology, life sciences and chemical organizations have
historically performed chemistry development using traditional laboratory
methods. To date, our products have not been as widely adopted by these
industries as we had expected. The commercial success of our products will
depend upon the adoption of these products as a method to develop chemical
compounds for these industries. In order to be successful, our products must
meet the performance and pricing requirements for chemistry development within
the pharmaceutical, biotechnology, life sciences and chemical industries.
Market acceptance will depend on many factors, including our ability to:  
    
    Convince prospective customers that our products are a cost-effective alternative to traditional methods and
other technologies that may be introduced for chemistry development.
    
    Convince prospective customers that our products provide the same or enhanced quality and
accuracy as compared with traditional methods and other new technologies that may be developed.
    
    Manufacture products in sufficient quantities with acceptable quality and at an acceptable cost.
    
    Install and service sufficient numbers of our instruments, particularly new instruments such as
the Advantage Series 3400 process chemistry workstation.
    
    Convince prospective customers that our products and our ability to supply and support our
products are equivalent or better as compared to competitor companies. If we cannot achieve these objectives, our products will not gain market
acceptance. We face risks associated with past and future acquisitions. Our success depends in part on our ability to continually enhance and broaden
our product offerings in response to changing technologies, customer demands
and competitive pressures. To meet these challenges, we have acquired
complementary businesses and may choose to acquire others in the future. We
completed our acquisition of ATSI in March 2001 and Jones Group in February
2002. During 2002 and 2003, we made significant progress integrating the Jones
Group business; however, we continue to have remaining integration activities
and projects, including the transition of the manufacturing and R&D operations
of the flash chromatography business to Foster City, California. Our failure
to completely and successfully integrate this business may materially affect
our business going forward. We do not know if we will be able to complete any future acquisitions, or
whether we will be able to successfully integrate any acquired business,
operate it profitably or retain its key employees. Integrating any business,
product or technology we acquire could be expensive and time consuming, and may
disrupt our ongoing business and distract our management. If we are unable to
effectively integrate any acquired entities, products or technologies, our
business may suffer. In addition, any amortization of goodwill or other assets
or charges resulting from the costs of acquisitions could negatively impact our
operating results. Our available cash and securities may be used to buy or
invest in companies or products, possibly resulting in significant
acquisition-related charges to earnings and dilution to our stockholders. Due
to volatile market conditions, the value of long live assets may be negatively
impacted, which may result in future, additional impairment charges. Moreover,
if we buy a company, we may have to incur or assume that companys liabilities,
including liabilities that are unknown at the time of acquisition. Our product development efforts may not produce commercially viable products. We continue to devote significant personnel and financial resources to research
and development activities to develop new products. We may not be successful
in developing new products, and we may never realize any benefits from such
research and development activities, which may not produce commercially viable
products. Our ability to increase our revenues and achieve and sustain
profitability is dependent upon our ability to successfully develop new and
commercially viable products. During the first half of 2003, we launched a new
product, the Advantage Series 3400 workstation and in the first quarter of
2004, we launched the FlashMaster Personal+ system and the Advantage Series
2410 personal screening synthesizer. Our ability to increase revenues in 2004
and beyond is dependent on the success of these products. Our instrument products have lengthy sales cycles, which could cause our
operating results to fluctuate significantly from quarter to quarter. Page 13 of 23




---



##### Table of Contents



Our ability to obtain customers for our instrument products depends, in
significant part, upon the perception that our products can help accelerate
efforts in chemical development. The sale of many of our instrument products
typically involves a significant technical evaluation and commitment of capital
by customers. Accordingly, the sales cycles of many of our instrument products
are lengthy and subject to a number of risks that are beyond our control,
including customers budgetary constraints and internal acceptance reviews.
Our revenues could fluctuate significantly from quarter to quarter, due to this
lengthy and unpredictable sales cycle. A large portion of our expenses,
including expenses for facilities, equipment and personnel, are relatively
fixed. Accordingly, if our revenues decline or do not grow as we anticipate,
we might not be able to correspondingly reduce our operating expenses. Our
failure to achieve our anticipated levels of revenues could significantly harm
our operating results for a particular fiscal period. Due to the possibility
of fluctuations in our operating results, we believe that quarter-to-quarter
comparisons of our operating results are not always a good indication of our
future performance. The capital spending policies of pharmaceutical, biotechnology, life sciences
and other chemical research organizations have a significant effect on the
demand for our instruments. We market our products to and receive our revenues principally from
pharmaceutical, biotechnology, life sciences and other chemical research
organizations, and the capital spending policies of these entities can have a
significant effect on the demand for our instruments. These policies are based
on a wide variety of factors, including the resources available for purchasing
research equipment, the spending priorities among various types of research
equipment and the policies regarding capital expenditures. In particular, the
volatility of the public stock market for biotechnology and related companies
has at certain times significantly impacted their ability to raise capital,
which has directly affected their capital spending budgets. In addition,
continued consolidation within these industries will likely delay and may
potentially reduce capital spending by pharmaceutical companies involved in
such consolidations. Any decrease or delay in capital spending by life
sciences companies could cause our revenues to decline and harm our
profitability. In order to be successful, we must recruit, retain and motivate key employees,
and failure to do so could seriously harm us. In order to be successful, we must recruit, retain and motivate executives and
other key employees, including those in managerial, technical, marketing and
sales positions. In particular, our product generation efforts depend on
hiring and retaining qualified technical personnel. Attracting and retaining
qualified sales representatives is also critical to our future. Experienced
management and technical, marketing and support personnel in the chemistry
instrumentation and consumables industry are in high demand and competition for
their talents is intense, although current economic conditions have moderated
this demand and competition for talent. The loss of key employees could have a
significant impact on our operations. We also must continue to motivate
employees and keep them focused on Argonauts strategies and goals, which may
be particularly difficult due to morale challenges posed by workforce
reductions and general uncertainty. Changes in management may be disruptive to
our business and may result in the departure of existing employees, customers
and/or research collaborators. It may take significant time to locate, retain
and integrate qualified management personnel. The life sciences industry is highly competitive and subject to rapid
technological change, and we may not have the resources necessary to
successfully compete. We compete with companies worldwide that are engaged in the development and
production of similar products. We face competition primarily from the
following three sectors:  
    
    pharmaceutical companies developing their own instruments;
    
    companies marketing products based upon parallel synthesis and other
non-traditional technologies, such as Mettler-Toledo AG and several
smaller instrument and reagent companies; and
    
    companies marketing conventional products based on traditional
chemistry methodologies, such as Biotage AB, and Isco, Inc. Many of our competitors have access to greater financial, technical, research,
marketing, sales, distribution, service and other resources than we do. We
face, and will continue to face, intense competition from organizations serving
the life sciences industry that are developing or marketing competing products
and technologies. These organizations may develop products or technologies
that are superior to our products or technologies in terms of performance, cost
or both. These organizations may offer price discounts or other concessions as
a competitive tactic that we may not be in a position to match. Page 14 of 23




---



##### Table of Contents



We will need to develop new applications for our products to remain
competitive. Our present or future products could be rendered obsolete or
uneconomical by technological advances of one or more of our current or future
competitors. In addition, the introduction or announcement of new products by
us or by others could result in a delay of or decrease in sales of existing
products, as customers evaluate these new products. Our future success will
depend on our ability to compete effectively against current technology as well
as to respond effectively to technological advances. We are exposed to the credit risk of some of our customers. Due to the prior slowdown in the economy, the credit risks relating to our
customers increased. Although we have programs in place to monitor and
mitigate the associated risk, there can be no assurance that such programs will
be effective in reducing our credit risks. We have experienced losses due to
customers failing to meet their obligations. Although these losses have not
been significant, future losses, if incurred, could harm our business and have
a material adverse effect on our operating results and financial conditions. Our direct worldwide sales force and network of distributors may not be
sufficient to successfully address the market for our products. We sell a major portion of our products through our own sales force. We may
not be able to build an efficient and effective sales and marketing force and
continue to expand our network of distributors. Our failure to build an
efficient and effective sales and marketing force could negatively impact sales
of our products, thus reducing our revenues and profitability. Because we outsource our instrument component, chemical intermediates and
product manufacturing, our ability to produce and supply our products could be
impaired. We outsource most of the production of components of our instruments to
vendors. We also outsource significant quantities of our high volume chemical
intermediates for our consumables products. Our reliance on our outside
vendors exposes us to risks including:  
    
    the possibility that one or more of our vendors could terminate their services at any time without notice;
    
    reduced control over pricing, quality and timely delivery, due to the difficulties in switching to alternative vendors; and
    
    the potential delays and expenses of seeking alternative sources of manufacturing services. Consequently, in the event that components from our suppliers or work performed
by our vendors are delayed or interrupted for any reason, our ability to
produce and deliver our products in sufficient quantities and at acceptable
costs would decline.
Additionally, certain components are provided by a single source. The effect
of a disruption of delivery of those single source components could impact our
ability to deliver product to our customers. We are exposed to fluctuations in the exchange rates of foreign currency and
the US dollar. As a global concern, we face exposure to adverse movements in foreign currency
and US dollar exchange rates. During the first quarter of 2004, approximately
58% of our net sales were exposed to foreign currency risk. During the same
period, approximately 20% of our operating expenses were exposed to foreign
currency risk. These exposures may change over time as business practices
evolve and could have a material adverse impact on our financial results. We
will monitor our exposure and may hedge against this and any other emerging
market currencies as necessary. Our business is subject to risks from international operations. We conduct business globally. Accordingly, our future results could be
materially adversely affected by a variety of uncontrollable and changing
factors including, among others, foreign currency exchange rates; regulatory,
political, or economic conditions in a specific country or region; trade
protection measures and other regulatory requirements; and natural disasters.
Any or all of these factors could have a material adverse impact on our future
international business. Our business is subject to the effects of general global economic conditions,
and particularly economic conditions in the United States and the United
Kingdom. Specifically, our business is subject to the effects of market
conditions in the pharmaceutical, biotechnology, life sciences and chemical
industries. In recent quarters, our operating results have been adversely
affected as a result of unfavorable economic conditions and reduced capital
spending in the United States, Europe, and Asia. If the economic conditions in
the United States and globally do not improve, or if we experience a worsening
in Page 15 of 23




---



##### Table of Contents



the global economic slowdown, we may continue to experience material adverse
impacts on our business, operating results, and financial condition. If we infringe on or misappropriate the proprietary rights of others or we are
unable to protect our own intellectual property rights our revenues could be
harmed. We may be sued for infringing on the intellectual property rights of others.
Intellectual property litigation is costly, and, even if we prevail, the cost
of such litigation could affect our profitability. In addition, litigation is
time consuming and could divert management attention and resources away from
our business. If we do not prevail in any litigation, in addition to any
damages we might have to pay, we could be required to stop the infringing
activity or obtain a license. We may not be able to obtain required licenses
on acceptable terms, or at all. In addition, some licenses may be
nonexclusive, and therefore, our competitors may have access to the technology
licensed to us. If we fail to obtain a required license or are unable to
design around a patent, we may be unable to sell some of our products, which
could harm our ability to compete and result in a decline in our revenues. Our success may depend on our ability to obtain and enforce patents on our
technology and to protect our trade secrets. Any patents we own may not afford
meaningful protection for our technology and products. Others may challenge
our patents and, as a result, our patents could be narrowed, invalidated or
rendered unenforceable. In addition, our current and future patent
applications may not result in the issuance of patents to us in the United
States or foreign countries. Moreover, competitors may develop products
similar to ours that are not covered by our patents. We try to protect our non-patented trade secrets by requiring our employees,
consultants and advisors to execute confidentiality agreements. However, we
cannot guarantee that these agreements will provide us with adequate protection
against improper use or disclosure of our trade secrets. Further, others may
independently develop substantially equivalent proprietary information and
techniques. If we are unable to protect our proprietary information and
techniques, our ability to exclude certain competitors from the market will be
limited. There may not be an active, liquid trading market for our common stock. We are listed on the NASDAQ National Market. There is no guarantee that an
active trading market for our Common Stock will be maintained on the NASDAQ
National Market. You may not be able to sell your shares quickly or at the
market price if trading in our stock is not active. If we fail to comply with
the continued listing requirements of the NASDAQ National Market, we may be
de-listed from trading on such market, and thereafter trading in our common
stock, if any, would likely be conducted through the NASDAQ SmallCap Market,
the over-the-counter market or on the Electronic Bulletin Board of the National
Association of Securities Dealers, Inc. Our stock price has been highly volatile, and your investment could suffer a
further decline in value. The trading price of our common stock has been highly volatile and ranged in
2004 from a per-share high of $2.68 to a low of $1.34 and could continue to be
subject to wide fluctuations in price in response to various factors, many of
which are
beyond our control, including;  
    
    actual or anticipated variations in quarterly operating results;
    
    failure to achieve, or changes in, financial estimates by securities analysts;
    
    announcements of new products or services or technological innovations by us or our competitors;
    
    conditions or trends in the pharmaceutical, biotechnology, life sciences and chemical industries;
    
    announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
    
    additions or departures of key personnel, including any directors;
    
    developments in the application or interpretation of new or
existing accounting pronouncements and reporting obligations;
    
    purchases or sales of our common stock, including any repurchases of our common stock under the existing or future
stock repurchase program; and
    
    developments regarding our patents or other intellectual property or that of our competitors. In addition, the stock market in general, and the NASDAQ Stock Markets
National Market and SmallCap Market and the market for technology companies in
particular, have experienced significant price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of
those companies. Further, there has been particular volatility in the market
prices of securities of life science companies. These broad market and
industry factors may negatively impact the market price of our common stock,
regardless of our operating performance. In the past, following Page 16 of 23




---



##### Table of Contents



periods of
volatility in the market price of a companys securities, securities class
action litigation has often been instituted. A securities class action suit
against us could result in substantial costs, potential liabilities and the
diversion of managements attention and resources. Sales of large numbers of shares of our common stock could cause our stock
price to decline. The market price of our common stock could decline as a result of sales of
substantial amounts of our common stock in the public market, or the perception
that these sales could occur. In addition, these factors could make it more
difficult for us to raise funds through future offerings of common stock. All
of the shares sold in our initial public offering are now freely transferable
without restriction or further registration under the Securities Act, except
for any shares purchased by our affiliates, as defined in Rule 144 of the
Securities Act. The remaining shares of common stock outstanding are
restricted securities as defined in Rule 144. These shares may be sold in the
future without registration under the Securities Act, to the extent permitted
by Rule 144 or other exemptions under the Securities Act. On March 1, 2001, we issued 666,667 shares of unregistered common stock in
connection with the acquisition of ATSI. On February 5, 2002, we registered 2,628,618 shares of common stock that are
reserved for issuance upon exercise of options granted under our stock option
and employee stock purchase plans. These shares can be sold in the public
market upon issuance, subject to restrictions under the securities laws
applicable to resales by affiliates. On February 20, 2002, we issued 572,152 shares of unregistered common stock in
connection with the acquisition of Jones Group. Anti-takeover provisions in our charter and bylaws and under Delaware law could
make a third-party acquisition of us difficult. Pursuant to our charter, our board of directors has the authority to issue up
to 10,000,000 shares of preferred stock and to determine the price, rights,
preferences, privileges and restrictions, including voting rights, of those
shares without any further vote of action by our stockholders. The issuance of
preferred stock could have the effect of making it more difficult for a third
party to acquire a majority of our outstanding voting stock. Our certificate
of incorporation and bylaws contain other provisions that could make it more
difficult for a third party to acquire us, even if doing so might be deemed
beneficial by our stockholders. These provisions could limit the price that
investors might be willing to pay in the future for shares of our common stock.
We are also subject to certain provisions of Delaware law that could delay,
deter or prevent a change in control of us. Recently Enacted and Proposed Changes in Securities Laws and Regulations are
Likely to Increase Our Costs The Sarbanes-Oxley Act of 2002 that became law in July 2002 requires changes in
some of our corporate governance and securities disclosure or compliance
practices. That Act also requires the SEC to promulgate new rules on a variety
of subjects, in addition to rule proposals already made, and Nasdaq has
proposed revisions to its requirements for companies that are Nasdaq-listed. We expect these developments to increase our legal
compliance costs, and to make some activities more time-consuming. We are
presently evaluating and monitoring regulatory developments and cannot estimate
the timing or magnitude of additional costs we may incur as a result. 
 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Our market risk disclosures have not changed significantly from those set forth
in the Managements Discussion and Analysis of Financial Condition and Results
of Operations in our Form 10-K for the year ended December 31, 2003 filed with
the Securities and Exchange Commission on March 30, 2004. 
 ITEM 4. CONTROLS AND PROCEDURES As of the end of the period covered by this report, the Company carried out an
evaluation, under the supervision and with the participation of its Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of its disclosure controls and procedures. Based on this
evaluation, the Companys Chief Executive Officer and Chief Financial Officer
concluded that the Companys disclosure controls and procedures as defined in
Rules 13(a)-14(c) under the Securities Exchange Act of 1934 (Exchange Act)
are effective to ensure that information required to be disclosed by the
Company in this report and other reports that it files under the Exchange Act
is recorded, processed, summarized and reported within the Page 17 of 23




---



##### Table of Contents



periods specified in
SEC rules and forms. It should be noted that the design of any system of
controls is based in part upon certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions, regardless of
how remote. There have been no significant changes in our internal controls over financial
reporting that occurred during our most recent fiscal quarter that has
materially affected or is reasonably likely to materially affect our internal
controls over financial reporting. 
 PART II. OTHER INFORMATION 
 ITEM 1: LEGAL PROCEEDINGS The Company is not currently involved in any material legal proceedings. 
 ITEM 2: CHANGES IN SECURITIES AND USE OF PROCEEDS Company Purchases of Common Stock The following table provides information about purchases by the Company during
the quarter ended March 31, 2004 of our common stock Total Number of
    
    Dollar Value ofShares Purchased
    
    Shares that MayTotal Number
    
    Average
    
    as Part of Publicly
    
    Yet Be Purchasedof Shares
    
    Price Paid
    
    Announced Plans
    
    Under the Plans orPeriod
    
    Purchased1
    
    Per Share
    
    or Programs2
    
    Programs1/01/04 - 1/31/04
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2/01/04 - 2/29/04
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    3/01/04 - 3/31/04
    
    
    50,000
    
    
    $
    1.62
    
    
    
    50,000
    
    
    $
    372,000
  1.
    
    All purchases were made pursuant to our publicly announced
repurchase program.2.
    
    On August 8, 2002, we announced the approval by our Board of
Directors of a stock repurchase program under which we may repurchase
up to $500,000 of our outstanding common stock through open market
transactions. The duration of our stock repurchase program is
open-ended and the timing and amount of repurchase transactions under
this program will depend on market conditions, corporate and
regulatory considerations, and will be funded from available working
capital. 
 ITEM 3: DEFAULTS UPON SENIOR SECURITIES None. 
 ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS None. 
 ITEM 5: OTHER INFORMATION None. Page 18 of 23




---



##### Table of Contents



ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K (a) Exhibits. The following exhibits have been file with this report. Number
    
    Description of Document2.1(c)
    
    Agreement and Plan of Merger dated January 31, 2001, by and among the Registrant, CPL Acquisition
Corp. and Camile Products, LLC.2.2(d)
    
    Agreement for the sale and purchase of the entire issued share capital of Jones Chromatography
Limited, dated February 11, 2002, by and among the Registrant and the former Jones Group
shareholders.3.1(a)
    
    Amended and Restated Certificate of Incorporation of the Registrant.3.2(g)
    
    Amended and Restated Bylaws of Registrant.4.3(c)
    
    Registration Rights Agreement dated March 1, 2001, by and among the Registrant and the members of
Camile Products, LLC.4.4(d)
    
    Registration Rights Agreement dated February 20, 2002, by and among the Registrant and the former
Jones Group shareholders.4.5(d)
    
    £7,650,000 Loan Note Instrument Creating Principal Amount Guaranteed Loan Notes 2004 guaranteed by
Barclays Bank PLC dated February 20, 2002.10.1(a)
    
    Amended and Restated Stockholder Rights Agreement, dated May 21, 1999.10.2(a)
    
    Offer Letter, dated October 29, 1996, from Registrant to David P. Binkley, Ph.D.10.3(a)
    
    Promissory Note Secured by Deed of Trust between the Registrant and David P. Binkley, dated December
17, 1996.10.4(a)
    
    Lease Agreement between the Registrant and Tanklage Family Partnership, dated July 9, 1999.10.5(a)
    
    Lease Agreement between the Registrant and MK Kojimachi Building Co., Ltd., dated September 16, 1997,
as amended.10.6(a)
    
    Lease Agreement between the Registrant and Personalvorsorgestiftung Rapp AG, dated April 16, 1997.10.7(a)
    
    License and Supply Agreement between the Registrant and Symyx Technologies, Inc., dated August 6,
1999.10.9(a)
    
    Form of Indemnification Agreement between the Registrant and each of its directors and officers.10.10(a)
    
    1995 Stock Plan.10.11(a)
    
    1995 Stock Plan Form of Stock Option Agreement.10.12(g)
    
    2000 Incentive Stock Plan, as amended.10.13(g)
    
    2000 Employee Stock Purchase Plan, as amended.10.14(b)
    
    Amendment to License and Supply Agreement between the Registrant and Symyx Technologies, Inc., dated
January 1, 2002.10.15(b)
    
    Agreement between the Registrant and David P. Binkley dated December 5, 2001.10.16(b)
    
    Agreement between the Registrant and John T. Supan dated January 10, 2002.10.17(e)
    
    License Agreement between Argonaut Technologies, Inc. and Symyx Technologies, Inc. dated August 21,
2002.10.18(f)
    
    Agreement between the Registrant and Jan K. Hughes dated December 9, 2002.10.19
    
    Agreement between the Registrant and Howard Goldstein dated April 16, 2004.10.20
    
    Lease Agreement between the Registrant and Metropolitan Life Insurance Company dated April 2, 2004.31.1
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.31.2
    
    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act .32.1
    
    Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(a)
    
    Incorporated by reference from our registration statement on Form S-1, registration number 333-35782,
declared effective by the Securities and Exchange Commission on July 18, 2000.(b)
    
    Incorporated by reference from our Form 10-K filed with the Securities and Exchange Commission on
April 1, 2002.(c)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on
March 16, 2001.
 Page 19 of 23




---



##### Table of Contents



(d)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on
March 6, 2002.(e)
    
    Incorporated by reference from our Form 10-Q filed with the Securities and Exchange Commission on
September 30, 2002. Certain portions of this exhibit have been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to such
omitted portions.(f)
    
    Incorporated by reference from our Form 10-K filed with the Securities and Exchange Commission on
March 31, 2003.(g)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on May
14, 2003.
  (b)
    
    Reports on Form 8-K.On February 24, 2004, the Company filed a report on Form 8-K providing the
contents of a press release issued by the Company announcing its financial
results for the year ended December 31, 2003.The Company filed no other reports on Form 8-K during the period ended
March 31, 2004. Page 20 of 23




---



##### Table of Contents



SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. Date: May 13, 2004
    
    ARGONAUT TECHNOLOGIES, INC.By:
    
    /s/ LISSA A. GOLDENSTEINLissa A. Goldenstein
President and Chief Executive OfficerBy:
    
    /s/ DAVID J. FOSTERDavid J. Foster
Sr. Vice President and Chief Financial Officer
 Page 21 of 23




---



##### Table of Contents



ARGONAUT TECHNOLOGIES, INC.
FORM 10-K
Quarterly Period Ended March 31, 2004 
 EXHIBIT INDEX Number
    
    Description of Document2.1(c)
    
    Agreement and Plan of Merger dated January 31, 2001, by and among the Registrant, CPL Acquisition
Corp. and Camile Products, LLC.2.2(d)
    
    Agreement for the sale and purchase of the entire issued share capital of Jones Chromatography
Limited, dated February 11, 2002, by and among the Registrant and the former Jones Group
shareholders.3.1(a)
    
    Amended and Restated Certificate of Incorporation of the Registrant.3.2(g)
    
    Amended and Restated Bylaws of Registrant.4.3(c)
    
    Registration Rights Agreement dated March 1, 2001, by and among the Registrant and the members of
Camile Products, LLC.4.4(d)
    
    Registration Rights Agreement dated February 20, 2002, by and among the Registrant and the former
Jones Group shareholders.4.5(d)
    
    £7,650,000 Loan Note Instrument Creating Principal Amount Guaranteed Loan Notes 2004 guaranteed by
Barclays Bank PLC dated February 20, 2002.10.1(a)
    
    Amended and Restated Stockholder Rights Agreement, dated May 21, 1999.10.2(a)
    
    Offer Letter, dated October 29, 1996, from Registrant to David P. Binkley, Ph.D.10.3(a)
    
    Promissory Note Secured by Deed of Trust between the Registrant and David P. Binkley, dated December
17, 1996.10.4(a)
    
    Lease Agreement between the Registrant and Tanklage Family Partnership, dated July 9, 1999.10.5(a)
    
    Lease Agreement between the Registrant and MK Kojimachi Building Co., Ltd., dated September 16,
1997, as amended.10.6(a)
    
    Lease Agreement between the Registrant and Personalvorsorgestiftung Rapp AG, dated April 16, 1997.10.7(a)
    
    License and Supply Agreement between the Registrant and Symyx Technologies, Inc., dated August 6,
1999.10.9(a)
    
    Form of Indemnification Agreement between the Registrant and each of its directors and officers.10.10(a)
    
    1995 Stock Plan.10.11(a)
    
    1995 Stock Plan Form of Stock Option Agreement.10.12(g)
    
    2000 Incentive Stock Plan, as amended.10.13(g)
    
    2000 Employee Stock Purchase Plan, as amended.10.14(b)
    
    Amendment to License and Supply Agreement between the Registrant and Symyx Technologies, Inc., dated
January 1, 2002.10.15(b)
    
    Agreement between the Registrant and David P. Binkley dated December 5, 2001.10.16(b)
    
    Agreement between the Registrant and John T. Supan dated January 10, 2002.10.17(e)
    
    License Agreement between Argonaut Technologies, Inc. and Symyx Technologies, Inc. dated August 21,
2002.10.18(f)
    
    Agreement between the Registrant and Jan K. Hughes dated December 9, 2002.10.19
    
    Agreement between the Registrant and Howard Goldstein dated April 16, 2004.10.20
    
    Lease Agreement between the Registrant and Metropolitan Life Insurance Company dated April 2, 2004.31.1
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.31.2
    
    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act.32.1
    
    Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  (a)
    
    Incorporated by reference from our registration statement on Form S-1, registration number
333-35782, declared effective by the Securities and Exchange Commission on July 18, 2000.(b)
    
    Incorporated by reference from our Form 10-K filed with the Securities and Exchange Commission on
April 1, 2002. Page 22 of 23




---



##### Table of Contents



(c)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on
March 16, 2001.(d)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on
March 6, 2002.(e)
    
    Incorporated by reference from our Form 10-Q filed with the Securities and Exchange Commission on
September 30, 2002. Certain portions of this exhibit have been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to
such omitted portions.(f)
    
    Incorporated by reference from our Form 10-K filed with the Securities and Exchange Commission on
March 31, 2003.(g)
    
    Incorporated by reference from our Form 8-K filed with the Securities and Exchange Commission on May
14, 2003. Page 23 of 23